News

The phase 3 trial will enroll no option as well as poor option patients with chronic and severe ischemia of the lower limb. No option patients are those

The acquisition of MRT, with its patented approach to high throughput miniature bioreactor equipment and disposables, expands Pall’s Total Fluid Management(TFM) capabilities in the $1 billion biopharmaceuticals process

Synergy will be implementing PharmaVigilant’s Inspire EDC System, Clinical Data Warehouse, Investigator Portal and I-Vault eTMF system to support the preparation, conduct and closeout of their phase II

Following two phase 2a studies that were conducted by Topigen with TPI 1020 in patients with asthma and COPD, NicOx and Topigen had recently been in active discussions

The agreement includes distribution in the US, Canada and Puerto Rico, and expands Sigma-Aldrich’s portfolio of chromatography solutions offered through its Supelco brand. In addition to the classic

According to the company, Zadaxin treatment given with the H1N1 vaccine led to a significant (p value < 0.01) increase in the percentage of subjects who seroconverted at

Reportedly, the ability to produce VaxInnate’s recombinant vaccine in a bacterial expression system will enable BE to manufacture vaccine at the company’s existing biotechnology facilities with microbial production

The new line produces high-performance polyester films, which will support the fast growing UK market. Klockner Pentaplast invested £3 Mio (E3.4 Mio /$4.4 Mio) for the expansion, with

ACH-1625 is an inhibitor of HCV NS3 protease that was discovered and is being developed by Achillion. HCV-infected subjects in the second dosing cohort (n=9, randomized to 6